HLB Life Science Co., Ltd.

HLB Life Science Co., Ltd., founded in 1998 and situated in Hwaseong, South Korea, operates a multifaceted business, having previously been known as Energy Solutions Co., Ltd. until its name change in December 2015. The company's core focus involves the global wholesale and distribution of pharmaceutical products, alongside significant investment in developing innovative medical treatments. Key among these are several drug candidates: Rivoceranib, a small-molecule tyrosine kinase inhibitor, is under development for a broad spectrum of cancers, including gastric, colorectal, hepatocellular, non-small cell lung, esophageal, thyroid, mesothelioma, and neuroendocrine tumors. Seclidemstat, an oral epigenetic small molecule, aims to restore normal gene expression and suppress tumor proliferation in various solid tumors like those found in the lung, breast, and prostate. Tegavivint, which functions as an inhibitor of the Wnt/β-catenin pathway, is being advanced for conditions such as desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of other solid tumor types. Beyond pharmaceuticals, HLB Life Science is also pioneering advanced medical technologies, including: LifeLiver, an extracorporeal bioartificial liver system. HepaStem, a therapeutic approach leveraging heterologous human adult liver-derived progenitor cells. HLBLS-200, a biocompatible polysaccharide-based powder designed to achieve adhesive hemostasis upon contact with blood. Additionally, the company maintains a robust presence in the energy sector. Its activities span waste heat recovery, cogeneration power generation, and the installation of facilities. It actively participates in various energy ventures, including solar power (photovoltaic generation), bioenergy, geothermal energy, waste-to-energy conversion, wind power, and fuel cell technologies. Furthermore, HLB Life Science undertakes projects focused on enhancing energy efficiency and implementing improvements to heating systems.